Dipeptidyl Peptidase-4 Inhibitors Associated Heart Failure Events in Adult Patients With Type-2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis.
INTRODUCTION: DPP-4 inhibitors use has been reported to cause heart failure events in patients with type-2 diabetes. The FDA had also issued warnings concerning increased risk of heart failure events ...
Validation of the Arabic Version of Patient Health Questionnaire-9 in Omani and Yemeni Patients With Chronic Physical Diseases.
BACKGROUND: Secondary depression frequently develops in people with chronic diseases, and it may hinder disease progress and treatment outcomes. This study aimed to examine the construct validity and ...
Patient Selection, Referral Framework and Emerging Therapies in Severe Ischemic Heart Failure: A State-of-the-Art Review.
Chronic or severe ischemic heart disease can lead to damaged or infarcted myocardium that can progress to heart failure. When evaluating revascularization, one should consider noninvasive assessments,...
Patient Selection, Referral Timing, and Advanced Heart Disease Therapy Options for Heart Failure with Reduced Ejection Fraction.
Advanced heart failure is characterized by persistent severe symptoms and functional limitations despite optimal medical therapy and carries significant morbidity and mortality. This article discusses...
Cardiac Contractility Modulation: Implications in Heart Failure, a Current Review.
Cardiac contractility modulation (CCM) is a novel therapeutic approach for heart failure patients, which utilizes nonexcitatory electrical myocardial stimulation in the absolute refractory period of t...
Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.
A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe and significantly improved patient-cen...
Remote Monitoring Devices and Heart Failure.
Remote patient monitoring (RPM) in patients with heart failure (HF) involves transmitting physiological data from devices to a health-care provider via a wireless connection with targeted intervention...
Cardiac Opioid System and Its Role in Heart Failure and Ischemia-Reperfusion Injury.
Opioid receptors and peptides act as modulators of cardiac and vascular function. These effects are mediated not only by central mechanisms but also via a local cardiac opioid system, which has gained...
Effects of Nurse-Led Interventions on Quality of Life and Self-Care Among Patients With Heart Failure: A Systematic Review.
BACKGROUND: Nurses are pivotal in promoting self-care among patients with heart failure (HF), particularly by educating them on how to prevent potential complications and rehospitalisations. Meanwhile...
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalizations, with obesity increasingly recognized as a central driver through expans...
Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1.
Insulin resistance (IR) is an underrecognized feature of type 1 diabetes (T1D), present even in lean individuals. Rising obesity rates have further amplified this burden, creating a mixed metabolic ph...
Device Management of Patients on Left Ventricular Assist Device Support: A Practical Review for the ICU Clinician.
Nonphysiologic continuous flow (cf) in the current era of left ventricular assist device (LVAD) support confers unique challenges in management, with greater preload/afterload sensitivity, reduced sys...
The Left Ventricular Assist Device Patient in the Intensive Care Unit: A Clinically Focused Guide for Intensivists.
Left ventricular assist devices (LVADs) are increasingly used for advanced heart failure patients. Meanwhile, ongoing improvements in durability have enhanced long-term device performance. Intensivist...
Permanent Left Ventricular Assist Devices: Long-Term Management and Outcomes.
This article outlines the historical development, physiologic principles, and contemporary clinical management of durable left ventricular assist devices, with a primary focus on the HeartMate 3 era. ...
Temporary Left Ventricular Assist Devices: Indications and Patient Selection.
Temporary percutaneous left ventricular assist devices (pLVADs), most prominently transvalvular microaxial flow pumps, have become central tools for contemporary cardiogenic shock care and for hemodyn...
Optimizing Mechanical Ventilation in Right Heart Failure.
In patients with acute respiratory distress syndrome, the prevalence of right ventricular dysfunction (RVD) has been documented as high as 60%, though more recent estimates suggest a lower incidence o...
A dyadic reminiscence intervention on mutuality for persons with heart failure and their spouse caregivers: A quasi-experimental study.
OBJECTIVE: Low mutuality between persons with heart failure (HF) and their spouse caregivers is associated with adverse outcomes in the dyads. However, dyadic interventions targeting enhanced mutualit...
Comorbidity Trajectories Before and After Hip Fracture in Elderly Patients: A Korean Nationwide Database Cohort Study.
BACKGROUND: Hip fractures in older adults often signal frailty and are associated with poor outcomes, including mortality and disability. Although a high burden of comorbidities is common, little is k...
Glucose-dependent insulinotropic polypeptide receptor agonism improves heart failure with antifibrosis through Akt-dependent nitric oxide signaling.
BACKGROUND: Cardiac fibrosis is a pathological remodeling process that contributes to the development and progression of heart failure. Although glucose-dependent insulinotropic polypeptide (GIP) may ...
Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure.
BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have become essential in the management of heart failure. Their prognostic benefits are consistent across older adults, frail, and under...